AbbVie Study on Treatment for Giant Cell Arteritis Meets Primary Endpoint
By Denny Jacob
AbbVie disclosed positive top-line results from a study on upadacitinib to treat adults with giant cell arteritis, an autoimmune disease.
The drugmaker said its Phase 3 study showed upadacitinib in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remission over a certain period of time.
Giant cell arteritis causes inflammation of medium and large arteries. It generally impacts people over the age of 50.
AbbVie also noted key secondary endpoints in the study were also met.
Upadacitinib is being studied in Phase 3 trials for alopecia areata and hidradenitis suppurativa, among others, in addition to giant cell arteritis.
Marketed under the name Rinvoq, the drug is approved in the U.S. to treat certain other inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
April 18, 2024 09:26 ET (13:26 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom